Press Releases

Date	Title	Company
18-Dec-2023	3D-Printed Maxillofacial Implants Industry Aims to Surpass US$ 1,119.1 Million by 2033-FMI Projection	MARKITWIRED
18-Dec-2023	Vaginal Specula Industry Gears Up for Explosive Growth, Projected to Exceed US$ 1,301.5 Million by 2033-FMI Study	MARKITWIRED
18-Dec-2023	Topical Wound Agents Industry Poised to Achieve US$ 3,520.0 Million in Revenue by 2033-FMI Projection	MARKITWIRED
18-Dec-2023	Virtual Companion Care Industry Soars Toward an Expected US$ 14.4 Million by 2033-FMI Projection	MARKITWIRED
18-Dec-2023	Veterinary Procedure Lights Industry Radiates Towards an Anticipated US$ 463.9 Million by 2033-FMI Projection	MARKITWIRED
18-Dec-2023	Osteonecrosis Treatment Industry Poised to Surge Beyond US$ 434.0 Million by 2033-FMI Projection	MARKITWIRED
18-Dec-2023	IRLAB Submits Request for an End-of-Phase 2 Meeting with the FDA for the Phase III-ready Mesdopetam Program	AccessWire
18-Dec-2023	Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration	Xlife Sciences AG
18-Dec-2023	Genetic Evolution: Gene Therapy Market Size Poised to Reach USD 46.5 billion by 2030, Surging at 22.8% CAGR	The Wire Times
18-Dec-2023	Unveiling Innovation: Digital Pathology Market Set for USD 17.91 Billion by 2030, Surging at 9.3% CAGR	The Wire Times
16-Dec-2023	CDBT Registers Magistrates Court of Queensland Judgments against Kenneth Maciora / Empire Relations Group	AccessWire
16-Dec-2023	Takeda obtient l’avis favorable du CHMP pour HYQVIA® en tant que traitement d’entretien chez les patients atteints de polyneuropathie inflammatoire démyélinisante chronique (PDIC)	Businesswire
16-Dec-2023	Takeda recibe la opinión positiva del CHMP para HYQVIA® como terapia de mantenimiento en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC)	Businesswire
16-Dec-2023	Takeda erhält positive CHMP-Stellungnahme für HYQVIA® als Erhaltungstherapie bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP)	Businesswire
16-Dec-2023	Alfa Chemistry Leads the Way to Unleash Power of Computational Solutions in Solid State Chemistry for Pharmaceutical Research	Alfa Chemistry
16-Dec-2023	PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer	Businesswire
16-Dec-2023	FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer	Businesswire
16-Dec-2023	Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Businesswire
16-Dec-2023	Amneal Announces Move to Nasdaq	Businesswire
16-Dec-2023	Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)	Businesswire